Objective:To study p16 methylation of BEP-2D cells during its malignant transformation.Methods:Normal BEP-2D cells and BEP-2D cells treated by cigarette smoke condensate(CSC) for 15 weeks(W-15),25 weeks(W-25),38 weeks(W-38) and 43 weeks(W-43)respectively were chosen to study the p16 methylation status by Nested methylation specific PCR (Nested-MSP).Results:The p16 methylation was found in W-15,W-25,W-38 and W-43 BEP-2D cells,but not in the normal BEP-2D cell.Conclusion:The p16 methylation may be considered as a kind of biology-marker of the early diagnosis of lung cancer because the p16 methylation occurs in the earlier period of lung cancer.

0.05);There are significant differences between treatment group and control group in moderate and severe patients(P

Objective:To study the phamacokinetics of Nalmefene hydrochloride. Methods:30 healthy Chinese volunteers were assigned to 3 groups according to randomized design, and each group were given respectively a single intravenous administration dose of 0.5 mg, 1mg and 2mg of Nalmefene hydrochloride. The electrospray ionization positive selected reaction monitoring detections for Nalmefene hydrochloride and allyln-oroxymorphone (the internal standard) in the plasma and in the urine were used. The pharmaceutical parameters were calculated by 3P87 software. Results: The limit of the detection for Nalmefene hydrochloride was 0.0008 ng/ml in plasma and 0.0003 ng/ml in urine. There were good linear relationship range from 0.04 to 625ng/ml in plasma and 0.2 to 625 ng/ml in the urine. The variation coefficient in day and days, and the recoveries fitted the clinical pharmacokinetic study requirements. After a single intravenous administration of 0.5 mg,1mg, and 2mg of Na-lmefene hydrochloride, the obtained pharmacokinetic parameters were respectively as follows:Cmax were(1.74?0.48)?g/L,(4.17?1.08) ?g/L,(7.88?2.89) ?g/L;t1/2? were(12.83?3.98) h,(12.6?6.4) h, (10.58?3.74) h;V were (3.45?0.16) L/kg;(4.11?0.0716)L/kg、(4.25?0.56)L/kg;CL were (0.81?0.11) L/(h?kg), (0.85?0.15)L/(h?kg), (0.87?0.11) L/(h?kg);AUC0-∞ were (21.62?9.34) (ng/L)*h,(24.89?8.52) (ng/L)*h, (35?11.2) ng/L)*h;the urine accumulatived exc-retory rate were (78?21)%,(71?29)%,(78?19)%. Conclusion: The determination method for Nalmefene hydro-chloride in the plasma and in the urine by the electrosprayionization positive selected reaction monitoring detections is exclusive, accurate, sensitive and suitable. Pharmacokinetic characteristics in 3 groups of human treated with intravenous administration were described by a two-compartment model. The pharmaceutical characteristics of doxycycline hydrochloride in human body were linear in the range of 0.5~2.0 mg.

In clinical practice, muscular atrophy is a common sign in children. Because of relatively thick subcutaneous fat in children, muscular atrophy is not easy to be discovered. In order to confirm the diagnosis earlier, it is very important to take history in detail, to observe the motor function, cry, the posture of sitting and standing carefully, to do the physical examination thoroughly, and to use the assistant test reasonably.

Objective To observe the clinical effects of pemetrexed chemotherapy combined with radiotherapy in brain metastases of lung adenocarcinoma patients.Methods The data of lung adenocarcinoma patients with brain metastases were conducted retrospectively diagnostic analysis,and they were stratified randomized divided into the observation group (26 cases) and the control group (25 cases).The observation group was treated with pemetrexed chemotherapy combined with radiotherapy; the control group was treated with radiotherapy alone.Brain metastases,quality of life,short-term efficacy,adverse reactions,and patients' survival period were observed.Results The efficacy and quality of life of patients in the observation group were improved significantly than those of the control group,and adverse reactions were mild,the survival period was not significant between two groups.Conclusions Pemetrexed in combination with radiation therapy for the treatment of brain metastases from lung adenocarcinoma can effectively improve the short-term efficacy and quality of life of patients,and the adverse reactions are mild,it possess great application value in the treatment of brain metastases of lung adenocarcinoma.

To confirm a patient's muscular dystrophy is a motor neuron amyotrophy or not,we should take history in detail,physical examination completely,and assistant test reasonably.The history include the first onset symptom such as dysarthrosis,dysphagia,weakness and muscular dystrophy in the hand.We should pay attention to the fasciculation,insensibility,sphincter problem,the symptom progress,and family history.The lab tests include serum creating kinas,electromyogram,muscle biopsy,and gene(SOD1,SMA)analysis.It is important distinguish motor neuron amyotrophy from other muscular dystrophy with the cause of the spinal anterior horn cells damage clear.

Asthma ; diagnosis ; therapy ; Humans ; Practice Guidelines as Topic ; Rhinitis, Allergic, Perennial ; diagnosis ; therapy

Angiogenesis Inhibitors ; adverse effects ; Antibodies, Monoclonal ; adverse effects ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Carcinoma, Non-Small-Cell Lung ; drug therapy ; Hemorrhage ; chemically induced ; Humans ; Hypertension ; chemically induced ; Lung Neoplasms ; drug therapy ; Proteinuria ; chemically induced ; Thromboembolism ; chemically induced

Constriction, Pathologic ; Humans ; Root Canal Obturation ; methods ; Root Canal Preparation ; methods ; Tooth Apex ; anatomy & histology ; pathology ; Tooth Diseases ; pathology ; therapy

BACKGROUND: The human leucocyte antigen (HLA) allele are now understood to be alternative DNA sequences at the same physical gene locus, which may or may not result in different phenotypic traits. The generation of a new allele is induced by various factors, but, whether the mutation would be exist after removing the causative factors need further investigation. OBJECTIVE: To confirm the new allele by DNA sequencing technique, in addition, to analyze the heritage of a HLA allele A~*9217 (No. of WHO registration: WHS10004629)DESIGN, TIME AND SETTING: The open experiment with DNA as observation object. The initial detection with polymerase chain reaction sequence-specific oligonucleotide (PCR-SSO) was performed at HLA Laboratory of Henan Provincial Red Cross Blood Center in November 2007, and the sequencing was performed at HLA Laboratory of DYNAL Biological Technology (Beijing) Co., Ltd. in February, 2008. MATERIALS: The proband (sample ID: 371xxxxx ) and other 8 family member was investigated, blood sample was collected at the HLA Laboratory.METHODS: Nine family members of A~*9217 carrier were typing for HLA- A, B, DRB1 using PCR-SSO and SBT methods for low-media and high resolution, and 3 red blood cell blood groups systems: ABO, MN and Rh was tested to assist analysis .MAIN OUTCOME MEASURES: Sequence alignment of HLA-A exon 3 in A~*9217 carriers.RESULTS: According to the results of the blood groups phonotype of ABO, MN, Rh systems and HLA, the new allele A~*9217 of the proband was paternal origin. However, the sequence of this allele is A*020301, which had 3 base difference in exon 3, the new allele appears 3 base change at 391 T>G, 414 C>G, 418 T>G, and this new sequence was found in proband's two children.CONCLUSION: The new allele A~*9217 is generated from proband's father mutation, which can pass it to his children. However, the further heritage of A~*9217 allele need exploring.